With alogliptin, which belongs to a new class of diabetes drugs called DPP-4 inhibitors, Takeda hopes to not only compete with Merck's drug Januvia, the only DPP-4 on the U.S. market, but also ...

Aggressive marketing of Merck & Co.'s new first-in-class diabetes drug Januvia has led to a strong launch, according to data compiled by ImpactRx Inc., a market research company that tracked ...

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

Those 10 lower prices – which ranged from a price cut of 79% for Type 2 diabetes drug Januvia to a 38% cut for cancer drug Imbruvica – will go into effect in January 2026.

Those 10 lower prices – which ranged from a price cut of 79% for Type 2 diabetes drug Januvia to a 38% cut for cancer drug Imbruvica – will go into effect in January 2026.

The White House announced the first batch of negotiated Medicare drug prices in August after negotiating for reduced prices for months. The 10 new lower prices — which ranged from a price cut of 79% ...

The Biden administration, in its last full weekday in office, announced the next 15 drugs up for Medicare price negotiation. Blockbuster diabetes drug Ozempic is on the list. That means the ...